Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 09, 2025 08:30 ET | Source: Ernexa Therapeutics Inc.

Ernexa Therapeutics Regains Compliance with Nasdaq Listing Requirements

CAMBRIDGE, Mass., July 09, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today...
June 25, 2025 08:30 ET | Source: Ernexa Therapeutics Inc.

Ernexa Therapeutics Expands Advisory Board to Form Integrated Scientific and Medical Advisory Board as it Prepares for Clinical Development

CAMBRIDGE, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today...
June 24, 2025 08:30 ET | Source: Ernexa Therapeutics Inc.

Ernexa Therapeutics Secures $6 Million in Second Closing Under Securities Purchase Agreement

CAMBRIDGE, Mass., June 24, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today...
June 10, 2025 09:30 ET | Source: Ernexa Therapeutics Inc.

Ernexa Therapeutics Announces 1-for-15 Reverse Stock Split

CAMBRIDGE, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today...
May 28, 2025 08:30 ET | Source: Ernexa Therapeutics Inc.

Ernexa Therapeutics Announces New Data to be Presented at ASCO Annual Meeting 2025

CAMBRIDGE, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today...
May 14, 2025 08:30 ET | Source: Ernexa Therapeutics Inc.

Ernexa Therapeutics Establishes Texas Subsidiary to Support Continued Development of ERNA-101 and Future Clinical Operations

CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today...
April 29, 2025 08:30 ET | Source: Ernexa Therapeutics Inc.

Ernexa Therapeutics Presented Promising Data on Innovative Cell Therapy Treatment at AACR Annual Meeting 2025

CAMBRIDGE, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, presented...
April 22, 2025 08:30 ET | Source: Ernexa Therapeutics Inc.

Ernexa Therapeutics Announces New Data to be Presented at AACR Annual Meeting 2025

CAMBRIDGE, Mass., April 22, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today...
April 03, 2025 08:55 ET | Source: Ernexa Therapeutics Inc.

Ernexa Therapeutics Closes New Funding Round

CAMBRIDGE, Mass., April 03, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today...
March 25, 2025 08:30 ET | Source: Ernexa Therapeutics

Eterna Therapeutics Changes Name to Ernexa Therapeutics to Reflect New Strategic Focus on Ovarian Cancer and Autoimmune Disease

Ernexa Therapeutics embarks on new strategic direction, shifting the company’s focus from delivering a cell therapy platform to prioritizing product development New tagline to emphasize the company’s...

Next Page keyboard_arrow_right